Brokers Set Expectations for FBIO Q1 Earnings

Fortress Biotech, Inc. (NASDAQ:FBIO) – Analysts at Roth Capital issued their Q1 2025 earnings per share estimates for Fortress Biotech in a research note issued on Tuesday, March 11th. Roth Capital analyst J. Wittes forecasts that the biopharmaceutical company will post earnings of $1.47 per share for the quarter. The consensus estimate for Fortress Biotech’s current full-year earnings is ($3.28) per share. Roth Capital also issued estimates for Fortress Biotech’s Q2 2025 earnings at $1.23 EPS, Q3 2025 earnings at $1.27 EPS and Q4 2025 earnings at $1.19 EPS.

Other equities research analysts also recently issued research reports about the company. HC Wainwright boosted their price target on Fortress Biotech from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Monday, November 18th. StockNews.com downgraded Fortress Biotech from a “hold” rating to a “sell” rating in a research report on Friday, November 15th. Finally, Roth Mkm restated a “buy” rating and set a $16.00 price objective (up previously from $15.00) on shares of Fortress Biotech in a research note on Tuesday. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Fortress Biotech presently has a consensus rating of “Moderate Buy” and an average target price of $15.67.

Fortress Biotech Trading Down 0.6 %

FBIO stock opened at $1.73 on Wednesday. The stock has a 50-day moving average price of $1.80 and a two-hundred day moving average price of $1.80. Fortress Biotech has a 12-month low of $1.36 and a 12-month high of $2.89. The company has a market cap of $47.76 million, a PE ratio of -0.57 and a beta of 1.75.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of FBIO. PVG Asset Management Corp lifted its stake in shares of Fortress Biotech by 140.1% in the third quarter. PVG Asset Management Corp now owns 373,790 shares of the biopharmaceutical company’s stock worth $540,000 after acquiring an additional 218,115 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Fortress Biotech by 125.1% in the fourth quarter. Renaissance Technologies LLC now owns 175,800 shares of the biopharmaceutical company’s stock worth $356,000 after acquiring an additional 97,712 shares in the last quarter. Envestnet Asset Management Inc. lifted its stake in shares of Fortress Biotech by 30.3% in the fourth quarter. Envestnet Asset Management Inc. now owns 239,594 shares of the biopharmaceutical company’s stock worth $485,000 after acquiring an additional 55,648 shares in the last quarter. Two Sigma Investments LP acquired a new position in shares of Fortress Biotech in the fourth quarter worth about $109,000. Finally, HB Wealth Management LLC lifted its stake in shares of Fortress Biotech by 93.1% in the fourth quarter. HB Wealth Management LLC now owns 106,850 shares of the biopharmaceutical company’s stock worth $232,000 after acquiring an additional 51,517 shares in the last quarter. Institutional investors and hedge funds own 96.51% of the company’s stock.

About Fortress Biotech

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.